MDS

Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.

Leah SherwoodMyelodysplastic Syndromes | March 24, 2023
The EC approval of luspatercept was based on results from the phase II BEYOND study.
Read More
Cecilia BrownMyelodysplastic Syndromes | March 6, 2023
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
Leah SherwoodMyelodysplastic Syndromes | March 6, 2023
MDS/AML are among independent predictors of COVID-19 treatment failure.
Cecilia BrownMyelodysplastic Syndromes | March 3, 2023
Oxidized mitochondrial DNA can “prime” MDS HSPCs for inflammasome activation.
Cecilia BrownMyelodysplastic Syndromes | February 14, 2023
Low-risk MDS can have high-risk features, but current MDS prognostic scoring systems may not capture key risk variables.
Cecilia BrownMyelodysplastic Syndromes | February 14, 2023
While the fifth edition “softened” the boundary between MDS and AML, it retains the 20% blast cutoff to define AML.
Cecilia BrownMyelodysplastic Syndromes | February 7, 2023
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Leah SherwoodMyelodysplastic Syndromes | February 7, 2023
Luspatercept reduced RBC transfusion units and visits in patients with lower-risk MDS with ring sideroblasts.
Cecilia BrownMyelodysplastic Syndromes | February 5, 2023
A panel recently made a consensus proposal to revise the IWG response criteria for higher-risk MDS.
Leah SherwoodMyelodysplastic Syndromes | January 27, 2023
The U.S. FDA granted Fast Track Designation to tamibarotene, an oral selective RARα agonist, for higher-risk MDS.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 26, 2023
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
Cecilia BrownAcute Myeloid Leukemia | January 26, 2023
A participant’s death led to a voluntary pause of a phase I/II trial evaluating MGTA-117 in relapsed/refractory AML and ...
Leah SherwoodMyelodysplastic Syndromes | January 19, 2023
Long-term safety data for luspatercept showed no new safety signals in lower-risk MDS.
Leah SherwoodMyelodysplastic Syndromes | January 19, 2023
Venetoclax plus azacitidine provided “clinically meaningful benefits” in R/R/ MDS post-HMA failure.
Leah SherwoodMyelodysplastic Syndromes | January 19, 2023
Researchers have developed and externally validated a clinical-molecular prognostic model for risk stratification in MDS.
Cecilia BrownMyelodysplastic Syndromes | January 6, 2023
Patients with MDS who received active therapy soon after their diagnosis had better outcomes than those who did not.
Leah SherwoodPrint | December 22, 2022
DocMatter members weigh in on the use of venetoclax in patients with higher-risk myelodysplastic syndromes.
Blood Cancers Today Staff WritersMeeting News | December 16, 2022
Survival rates for MDS/MPN overlap syndromes vary significantly by clinical entity.
Blood Cancers Today Staff WritersMeeting News | December 16, 2022
A phase III trial confirmed the efficacy of lenalidomide in transfusion-dependent MDS patients.
Blood Cancers Today Staff WritersMeeting News | December 16, 2022
MDS patients with del5q and one additional non-del20q cytogenetic abnormality are at higher risk.
Blood Cancers Today Staff WritersMeeting News | December 16, 2022
Researchers formulated an optimal dosing schedule for the oral-fixed dose combination of decitabine and cedazuridine in MDS.
Leah SherwoodMeeting News | December 15, 2022
Patients with MDS or AML experienced a reduction in the allele frequency of TP53 mutations in as early as cycle three.
Blood Cancers Today Staff WritersMeeting News | December 15, 2022
Blast quantification modalities vary substantially and could significantly impact treatment decisions in patients with MDS.
Chadi Nabhan, MD, MBA, FACPMeeting News | December 13, 2022
Phillip Scheinberg, MD, talk about CHIP and the IPSS-M in MDS with Chadi Nabhan, MD, host of The HemOnc Pulse, during ASH.
Cecilia BrownVideo Insights | December 13, 2022
Roger Lyons, MD, FACP, discusses challenges and future directions in treating patients with higher-risk MDS.
Keightley AmenMeeting News | December 11, 2022
A recent study evaluated patients with rare myeloid neoplasms who had NPM1 mutations.
Keightley AmenMeeting News | December 11, 2022
The IPSS-M Risk Stratification Model led to reclassification of almost half of patients with hypoplastic MDS.
Keightley AmenMyelodysplastic Syndromes | December 11, 2022
The number of cells with chromosomal abnormalities was significantly associated with clinical features and outcomes in MDS.
Cecilia BrownMeeting News | December 11, 2022
Most patients with lower-risk MDS who had low transfusion burden before luspatercept achieved transfusion independence.
Cecilia BrownMeeting News | December 11, 2022
Roger Lyons, MD, FACP, discusses a real-world retrospective observational study of treatment and survival in MDS.
Keightley AmenMeeting News | December 10, 2022
SX-682 was effective and well tolerated at a dose of 200 mg twice daily in patients with MDS.
Keightley AmenMeeting News | December 10, 2022
A recent study evaluated the safety profile of deferiprone in patients with myelodysplastic syndromes (MDS).
Leah SherwoodMyelodysplastic Syndromes | December 10, 2022
A new machine-learning model based exclusively on clinical variables high prognostic accuracy for predicting MDS outcomes.
Cecilia BrownMyelodysplastic Syndromes | December 8, 2022
Patients with MDS or TP53-mutated acute leukemias who underwent HSCT had a one-year OS rate of 48.4%.
Cecilia BrownMeeting News | December 8, 2022
Venetoclax plus azacitidine maintenance after allogeneic HSCT led to a one-year OS rate of 70% in patients with AML/MDS.
Cecilia BrownMeeting News | December 8, 2022
More than one-third of patients with MDS and their caregivers had “concerning levels of depression and/or anxiety."
Cecilia BrownMyelodysplastic Syndromes | December 7, 2022
Patients aged 80 years and older and the lowest-risk patients with MDS are “more likely to die from competing causes."
Cecilia BrownMyelodysplastic Syndromes | December 7, 2022
A CR with partial hematologic recovery leads to "similar survival and duration on therapy” as a CR in patients with MDS.
Cecilia BrownMyelodysplastic Syndromes | December 7, 2022
Decitabine did not improve event-free survival over hydroxyurea in patients with advanced myeloproliferative CMML.
Cecilia BrownPrint | November 23, 2022
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Venetoclax and azacitidine in R/R MDS demonstrated a manageable safety profile with meaningful clinical benefits...
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Further development of BI 836858 was discontinued after it failed to elicit a response in transfusion-dependent.
Leah SherwoodMyelodysplastic Syndromes | November 8, 2022
Azacitidine may be a treatment option for patients with SAID associated with MDS and CMML.
Kerri FitzgeraldMyelodysplastic Syndromes | October 19, 2022
A prospective study failed to confirm the general predictive value of a biomarker-driven prediction model.
Kerri FitzgeraldMyelodysplastic Syndromes | October 19, 2022
HLA-matched sibling donors are the preferred transplant choice for MDS.
Kerri FitzgeraldMyelodysplastic Syndromes | October 4, 2022
A study showed "unexpected" results related to race and MDS survival...
Leah SherwoodMyelodysplastic Syndromes | October 4, 2022
Nearly a third (30%) of patients with higher-risk MDS have an overexpression of the RARA gene...
Cecilia BrownMyelodysplastic Syndromes | October 4, 2022
The classification process is mainly based on two processes, class discovery and class prediction...
Leah SherwoodMyelodysplastic Syndromes | October 3, 2022
Phillip Scheinberg, MD, PhD, discusses myelodysplastic syndromes at the 2022 SOHO Annual Meeting...
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
Blood Cancers Today interviewed Dr. Diez-Campelo after her presentation titled, “Treatment of Lower Risk MDS.”
Leah SherwoodMyelodysplastic Syndromes | October 2, 2022
Researchers retrospectively assessed 135 untreated patients with MDS who later developed HMA-F...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Kerri FitzgeraldMyelodysplastic Syndromes | September 30, 2022
Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting...
Leah SherwoodMyelodysplastic Syndromes | September 30, 2022
The outcomes of AML transformation after HMA-failure MDS remain extremely poor...
Leah SherwoodMyelodysplastic Syndromes | September 30, 2022
Azacitidine is the current standard of care, and magrolimab is a monoclonal antibody blocking CD47 expression...
Kerri FitzgeraldMyelodysplastic Syndromes | September 29, 2022
During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes...
Leah SherwoodMyelodysplastic Syndromes | September 29, 2022
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Leah SherwoodMyelodysplastic Syndromes | September 28, 2022
Dr. Garcia-Manero talks about what a “total approach” to MDS means to him...
Leah SherwoodMyelodysplastic Syndromes | September 28, 2022
The number of HSCTs performed for MDS is increasing, yet HSCT remains under-utilized for MDS...
Cecilia BrownMyelodysplastic Syndromes | September 28, 2022
Guillermo Garcia-Manero, MD, was honored during the society’s 10th annual meeting in Houston, Texas...
Leah SherwoodMyelodysplastic Syndromes | September 28, 2022
The study sought to understand the characteristics and molecular profile of h-MDS in comparison with n-MDS...
Leah SherwoodAcute Myeloid Leukemia | September 22, 2022
Guillermo Garcia-Manero, MD, gives his perspective.
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
It led to an overall response rate of 74% in patients with newly diagnosed IDH2-mutated myelodysplastic syndrome.
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
Pathogenic or likely pathogenic germline variants are found in around a fifth of patients with MDS diagnosed at or before 40.
Leah SherwoodMyelodysplastic Syndromes | September 12, 2022
The results of the trial were presented during the 2022 ESMO Congress by Chunkang Chang, MD, PhD.
Cecilia BrownMyelodysplastic Syndromes | August 25, 2022
The FDA granted Orphan Drug Designation to tamibarotene for the treatment of MDS in February 2022.
Leah SherwoodMyelodysplastic Syndromes | August 16, 2022
The researchers analyzed data from previously untreated adult patients with low- or intermediate-risk MDS.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
The study included patients who had anemia due to lower-risk MDS with ring sideroblasts and received regular RBC transfusions
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
A phase II, multicenter, open-label trial found that eprenetapopt plus azacitidine was well tolerated and safe.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
The trial examined selinexor's effect on treatment outcomes in patients with AML and high-risk MDS.
Leah SherwoodMyelodysplastic Syndromes | August 12, 2022
The global, phase III PANTHER trial investigated the comparison in higher-risk MDS, higher-risk CMML, and AML.
Kerri FitzgeraldMyelodysplastic Syndromes | August 10, 2022
Guillermo Garcia-Manero, MD, discusses where the field of hematologic oncology is headed.
Leah SherwoodPrint | August 6, 2022
Dr. Garcia-Manero discusses research from the MDS/AML Moon and what he’s looking forward to as President-Elect of SOHO.
Kerri FitzgeraldMyelodysplastic Syndromes | August 4, 2022
The MDS/AML Moon Shot® program supports research projects that would be difficult to obtain traditional funding for.
Leah SherwoodMyelodysplastic Syndromes | July 14, 2022
A retrospective study showed that response rate and survival outcome are still modest for high-risk patients.
Cecilia BrownMyelodysplastic Syndromes | July 14, 2022
The study analyzed 70 transplant-ineligible patients with high-risk MDS and MDS/AML with less than 30% of myeloblasts.
Leah SherwoodMyelodysplastic Syndromes | July 14, 2022
The new IPSS-Molecular model generates a unique risk score for individual patients.
Leah SherwoodMyelodysplastic Syndromes | July 7, 2022
Researchers reviewed the FDA Adverse Event Reporting System and the EudraVigilance database for adverse event reports.
Leah SherwoodMyelodysplastic Syndromes | July 7, 2022
Treosulfan demonstrated a significant improvement in EFS over RIC busulfan with a clinically meaningful benefit.
Leah LawrenceMyelodysplastic Syndromes | June 27, 2022
HMAs are currently used as a first-line treatment for patients with MDS, but their mechanism of action is not clear.
Leah SherwoodAcute Myeloid Leukemia | June 24, 2022
The presence of TP53-mutated MDS and AML with CK points to a single aggressive disease.
Leah SherwoodAcute Myeloid Leukemia | June 23, 2022
TP53-mutated AML and MDS-EB do not differ with respect to their clinical and molecular characteristics or survival outcomes.
Leah SherwoodMyelodysplastic Syndromes | June 23, 2022
Study finds BM CH was present in nearly two-thirds of BPDCN patients and particularly prevalent in elderly patients.
Kerri FitzgeraldAcute Myeloid Leukemia | June 23, 2022
The FDA and Finnish Medicines Agency cleared the investigational new drug application for bexmarilimab.
Kerri FitzgeraldMyelodysplastic Syndromes | June 23, 2022
Dr. Scheinberg talks about how his father influenced his career and how he built an advanced hematology program in Brazil.
Leah LawrenceChronic Myeloid Leukemia | May 26, 2022
The phase I/II study will assess the safety and tolerability of the drug.
Leah LawrenceAcute Myeloid Leukemia | May 26, 2022
The hold was initiated after a reported death of a trial participant.
Leah LawrenceAcute Myeloid Leukemia | April 6, 2022
The FDA has put a partial hold on a clinical trial of emavusertib after the death of a patient.
Sabrina AhleAcute Myeloid Leukemia | February 7, 2022
The hold follows reports of a discrepancy in suspected unexpected serious adverse events between treatment arms.
Sagar Lonial, MD, FACPMyeloma | February 2, 2022
Editor-in-Chief Sagar Lonial, MD, FACP, introduces the new publication from SOHO.
Susan O'Brien, MDAcute Lymphoblastic Leukemia | February 1, 2022
At SOHO 2021, Susan O'Brien, MD, and Hagop Kantarjian, MD, addressed trends in hematologic malignancies.
Rob DillardMyelodysplastic Syndromes | January 8, 2022
Jesus D. Gonzalez-Lugo, MD, and colleagues, presented the findings at the 2021 ASH Annual Meeting.
Patrick DalyMyelodysplastic Syndromes | January 8, 2022
Results from the phase II IDIOME trial suggest that ivosidenib had good tolerability and significant efficacy.
Leah LawrenceMyelodysplastic Syndromes | January 8, 2022
These findings were shared at the 2021 ASH Annual Meeting by investigator Elsa Bernard, PhD.
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Latest News

March 24, 2023